9M 2023 Financial Overview

9M 2023: R&D update Lundbeck's R&D pipeline is substantially transformed Biology Hormonal/ neuropeptide signaling Project Area Phase I Phase II Phase III Filing/Launch Eptinezumab (anti-CGRP mAb)¹) Eptinezumab (anti-CGRP mAb)¹) Lu AG09222 (anti-PACAP mAb)4) Lu AG13909 (anti-ACTH mAb)5) 1) Migraine prevention 2) SUN-studies 1) Cluster headache CHRONICLE³) ALLEVIATE Migraine prevention Neuro-hormonal dysfunctions Circuitry / Brexpiprazole neuronal biology 6) Brexpiprazole Aripiprazole 2-month injectable MAGL inhibitor program? Lu AF28996 (D₁/D2 agonist) Agitation in Alzheimer's dementia PTSD Schizophrenia & bipolar I disorder Neurology/Psychiatry Parkinson's disease Protein aggregation, folding and clearance Lu AF82422 (anti a-synuclein mAb) Synucleinopathies (MSA) Neuroinflammation / neuroimmunology Lu AG22515 (anti-CD40L blocker) Neurology AMULET 19 1) CGRP: Calcitonin gene-related peptide. 2) Two phase III clinical trials, supporting registration in Asia, including China and Japan: SUNRISE, and SUNSET trials. 3) Long-term safety study. 4) PACAP: Pituitary adenylate cyclase activating peptide. 5) Adrenocorticotropic hormone. 6) Acts as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors. 7) Monoacylglycerol lipase inhibitor ("MAG lipase") previously denominated '466/Lu AG06466. AADAD: agitation associated with dementia due to Alzheimer's disease. Note: Brexpiprazole AADAD and Aripiprazole 2-month injectable formulation approved in the U.S. Lundbeck

View entire presentation